Key result
Concomitant ECMO and CRRT had a 65.4% (17/26) mortality rate, a 4.2% technical circuit failure rate, and 0% dialysis dependence among 90-day survivors.
Why the study?
Combining extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT) raises clinical and technical questions regarding vascular access, circuit pressures, anticoagulation, and kidney recovery.
Cohort (n=26)
No
Concomitant CRRT during ECMO is technically feasible with low circuit failure rates (4.2%) and favorable renal recovery among survivors, though overall mortality remains high (65.4%).
Answers are grounded in this paper and cite their sources.
High mortality in ECMO-CRRT patients warrants careful selection; leaves open optimal circuit and anticoagulation strategies.
Background: Combining extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT) raises questions concerning vascular access, circuit pressures, anticoagulation, and kidney recovery. We describe a single-center experience and frame the findings within the contemporary literature. Methods: Adults receiving concomitant ECMO and CRRT between January 2023 and June 2026 were retrospectively studied. Circuit performance, anticoagulation strategy, in-hospital mortality and kidney outcomes after intensive care unit discharge were described. Results: Twenty-six patients received CRRT during ECMO; 16 were managed with an integrated configuration and 10 with a dedicated dialysis catheter. Regional citrate anticoagulation was used in 49 of 72 CRRT circuits (68.1%). Overall mortality rate was 17/26 (65.4%). Among 72 CRRT circuits delivered during ECMO support, only three (4.2%) were interrupted because of technical failure. All 11 patients who survived to ECMO discontinuation continued to require CRRT; median observed post-ECMO CRRT duration was 17 days. At 90 days after ICU discharge, five of eight survivors with available kidney function follow-up had recovered to baseline and three had new-onset CKD; none of the nine survivors remained KRT-dependent. Conclusions: The combined use of ECMO and CRRT represents an evolving frontier of multiorgan support in a high-mortality population, in whom improving management and outcomes remains a major unmet need. This complex support requires technical expertise, an understanding of circuit interactions, and awareness of patient-specific clinical challenges and anticipated trajectories to enable individualized management. Nephrological care should therefore extend beyond circuit integration and the acute phase, encompassing kidney support and subsequent renal recovery.
No takes yet. Share an insight, caveat, or question.
Simone et al. (2026) conducted a cohort in Critical illness requiring concomitant ECMO and CRRT (n=26). Concomitant ECMO and continuous renal replacement therapy (CRRT) was evaluated on Overall mortality and kidney outcomes after intensive care unit discharge. Concomitant ECMO and CRRT had a 65.4% (17/26) mortality rate, a 4.2% technical circuit failure rate, and 0% dialysis dependence among 90-day survivors.
Synapse has enriched 10 related papers. Consider them for comparative context: